Abstract
Background: Current treatments for neurodegenerative diseases are challenging, due to the absence of fully effective medicines. One of the major problems associated to these is the occurrence of non-targeting events, which leads to adverse effects and requires frequent dose administration.
Methods: Researches have been performed to develop new drug delivery systems administrated by alternative routes. For example, the direct nose-to-brain delivery of drugs by means of lipid nanoparticles, such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), has been showing promising results.
Results: Among the advantages of intranasal administration is the avoidance of passing the blood-brain barrier (BBB) to reach the central nervous system (CNS), allowing the direct delivery of drugs to the brain by a noninvasive way, minimizing systemic exposure and prolonging residence time. This review article discusses the advantages of using SLN and NLC for direct nose-to-brain drug delivery. A brief reference to other lipid-based carriers (liposomes, nanoemulsions and microemulsions) is also provided.
Conclusion: The benefits of using SLN and NLC for improve nasal drug delivery have been demonstrated by in vitro, ex vivo and in vivo experiments. However, more in vivo animal studies are needed for advance to human clinical trials and reach clinics.
Keywords: Nasal/intranasal administration, neurodegenerative diseases, nose-to-brain, nanostructured lipid carriers, solid lipid nanoparticles, liposomes, nanoemulsions, microemulsions.
Current Pharmaceutical Design
Title:Intranasal Lipid Nanoparticles for the Treatment of Neurodegenerative Diseases
Volume: 23 Issue: 43
Author(s): S. Cunha, H. Almeida, M.H. Amaral*, J.M. Sousa Lobo and A.C. Silva*
Affiliation:
- Laboratory of Pharmaceutical Technology/Centre of Research in Pharmaceutical Sciences, Faculty of Pharmacy, Porto University, Porto,Portugal
- Laboratory of Pharmaceutical Technology/Centre of Research in Pharmaceutical Sciences, Faculty of Pharmacy, Porto University, Porto,Portugal
Keywords: Nasal/intranasal administration, neurodegenerative diseases, nose-to-brain, nanostructured lipid carriers, solid lipid nanoparticles, liposomes, nanoemulsions, microemulsions.
Abstract: Background: Current treatments for neurodegenerative diseases are challenging, due to the absence of fully effective medicines. One of the major problems associated to these is the occurrence of non-targeting events, which leads to adverse effects and requires frequent dose administration.
Methods: Researches have been performed to develop new drug delivery systems administrated by alternative routes. For example, the direct nose-to-brain delivery of drugs by means of lipid nanoparticles, such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), has been showing promising results.
Results: Among the advantages of intranasal administration is the avoidance of passing the blood-brain barrier (BBB) to reach the central nervous system (CNS), allowing the direct delivery of drugs to the brain by a noninvasive way, minimizing systemic exposure and prolonging residence time. This review article discusses the advantages of using SLN and NLC for direct nose-to-brain drug delivery. A brief reference to other lipid-based carriers (liposomes, nanoemulsions and microemulsions) is also provided.
Conclusion: The benefits of using SLN and NLC for improve nasal drug delivery have been demonstrated by in vitro, ex vivo and in vivo experiments. However, more in vivo animal studies are needed for advance to human clinical trials and reach clinics.
Export Options
About this article
Cite this article as:
Cunha S. , Almeida H., Amaral M.H. *, Lobo Sousa J.M. and Silva A.C.*, Intranasal Lipid Nanoparticles for the Treatment of Neurodegenerative Diseases, Current Pharmaceutical Design 2017; 23 (43) . https://dx.doi.org/10.2174/1381612824666171128105305
DOI https://dx.doi.org/10.2174/1381612824666171128105305 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Approach for Neuronal Disease by Regulating Reninangiotensin System
Current Hypertension Reviews Editorial [Hot topic: Neuroprotection in ALS: From Pathology to Treatment (Guest Editors: Gabriele Siciliano and Luigi Murri)]
CNS & Neurological Disorders - Drug Targets From the Editors Perspective: Inflammatory Glial Cells of the Nervous System: Assistants or Assassins?
Current Neurovascular Research CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Progresses of Novel Natural Products and Their Derivatives/ Analogs as Anti-Alzheimer Candidates: an Update
Mini-Reviews in Medicinal Chemistry Histone Deacetylase 2 in the Mouse Hippocampus: Attenuation of Age- Related Increase by Caloric Restriction
Current Alzheimer Research RNA Metabolism in Neurodegenerative Disease
Current Chemical Biology Trifluoroethanol-induced Activity and Structural Changes in Bos taurus Copper- and Zinc-containing Superoxide Dismutase
Protein & Peptide Letters Dimerization and Ion Binding Properties of S100P Protein
Protein & Peptide Letters Pharmaceutical Strategies for Activating Sirtuins
Current Pharmaceutical Design Syntheses of Ethyl Pyruvate’s Bioisosteres Inhibiting Inducible Nitric Oxide Production in Lipopolysaccharide-induced BV2 Cells
Letters in Drug Design & Discovery Programmed Cell Death Mechanisms in Neurological Disease
Current Molecular Medicine Dual Functional Small Molecule Probes as Fluorophore and Ligand for Misfolding Proteins
Current Organic Chemistry Viral Induced Oxidative and Inflammatory Response in Alzheimer’s Disease Pathogenesis with Identification of Potential Drug Candidates: A Systematic Review using Systems Biology Approach
Current Neuropharmacology The Underlying Role of Oxidative Stress in Neurodegeneration: A Mechanistic Review
CNS & Neurological Disorders - Drug Targets Tackling Chronic Pain and Inflammation through the Purinergic System
Current Medicinal Chemistry Tissue Distribution of Glutamate Carboxypeptidase II (GCPII) with a Focus on the Central and Peripheral Nervous System
Current Medicinal Chemistry Life and Death of Nerve Cells: Therapeutic Cytokine Signaling Pathways
Current Signal Transduction Therapy Mesenchymal Stem Cells Targeting of Systemic Disorders in Age-related Macular Degeneration
Current Tissue Engineering (Discontinued) Common Themes in RNA Subcellular Transport, Stress Granule Formation and Abnormal Protein Aggregation
Current Chemical Biology